Literature DB >> 24664937

Tandem high-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuro-ectodermic tumors.

Christelle Dufour1, Virginie Kieffer, Pascale Varlet, Marie Anne Raquin, Frederic Dhermain, Stephanie Puget, Dominique Valteau-Couanet, Jacques Grill.   

Abstract

BACKGROUND: To assess the feasibility and effectiveness of high-dose chemotherapy (HDC) with stem cell support followed by conventional craniospinal radiotherapy (RT) as treatment for children older than 5 years of age with newly diagnosed high-risk medulloblastoma (MB) or supratentorial PNET (sPNET). PROCEDURE: Between May 2001 and April 2010, 24 children older than 5 years of age (MB = 21; sPNET = 3), fulfilling inclusion criteria at diagnosis, were treated at Gustave Roussy. After conventional chemotherapy, they received two courses of high-dose thiotepa (600 mg/m(2)) followed by craniospinal RT.
RESULTS: The median follow-up was 4.4 years (range, 0.8-11.3 years). For children with metastatic MB, the 5-year event-free survival (EFS) and overall survival (OS) were 72% and 83%, respectively. The toxicity was manageable. No toxic death occurred. At the most recent evaluation, among the 24 children who had at least one Full Scale Intellectual Quotient (FSIQ) examination at a median follow-up of 3.79 years after diagnosis, the mean estimated FSIQ was 82 (range, 56-114).
CONCLUSIONS: In children with metastatic MB, tandem HDCT with ASCT followed by conventional craniospinal RT proved its feasibility without jeopardizing survival.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  childhood; high-dose chemotherapy; medulloblastoma

Mesh:

Year:  2014        PMID: 24664937     DOI: 10.1002/pbc.25009

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  13 in total

Review 1.  Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities.

Authors:  John Glod; Gilbert J Rahme; Harpreet Kaur; Eric H Raabe; Eugene I Hwang; Mark A Israel
Journal:  J Pediatr Hematol Oncol       Date:  2016-05       Impact factor: 1.289

2.  Management of hydrocephalus in pediatric metastatic tumors of the posterior fossa at presentation.

Authors:  Luc Le Fournier; Matthieu Delion; Maxime Esvan; Emilie De Carli; Céline Chappé; Philippe Mercier; Philippe Menei; Laurent Riffaud
Journal:  Childs Nerv Syst       Date:  2017-05-11       Impact factor: 1.475

3.  Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients.

Authors:  David R Raleigh; Bryan Tomlin; Benedict Del Buono; Erika Roddy; Katherine Sear; Lennox Byer; Erin Felton; Anu Banerjee; Joseph Torkildson; David Samuel; Biljana Horn; Steve E Braunstein; Daphne A Haas-Kogan; Sabine Mueller
Journal:  J Neurooncol       Date:  2016-10-24       Impact factor: 4.130

4.  Prognostic relevance of clinical and molecular risk factors in children with high-risk medulloblastoma treated in the phase II trial PNET HR+5.

Authors:  Christelle Dufour; Stephanie Foulon; Anne Geoffray; Julien Masliah-Planchon; Dominique Figarella-Branger; Valerie Bernier-Chastagner; Laetitia Padovani; Léa Guerrini-Rousseau; Cecile Faure-Conter; Celine Icher; Anne-Isabelle Bertozzi; Pierre Leblond; Tasnime Akbaraly; Franck Bourdeaut; Nicolas André; Celine Chappé; Pascale Schneider; Emilie De Carli; Pascal Chastagner; Claire Berger; Julien Lejeune; Christine Soler; Natacha Entz-Werlé; Marie-Bernadette Delisle
Journal:  Neuro Oncol       Date:  2021-07-01       Impact factor: 12.300

5.  BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma.

Authors:  Ping Zhao; Jacob Hall; Mary Durston; Austin Voydanoff; Elizabeth VanSickle; Shannon Kelly; Abhinav B Nagulapally; Jeffery Bond; Giselle Saulnier Sholler
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

6.  Radiation for ETMR: Literature review and case series of patients treated with proton therapy.

Authors:  Sergio Jaramillo; David R Grosshans; Nancy Philip; Ali Varan; Canan Akyüz; Mary Frances McAleer; Anita Mahajan; Susan L McGovern
Journal:  Clin Transl Radiat Oncol       Date:  2018-11-07

7.  Promising survival rate but high incidence of treatment-related mortality after reduced-dose craniospinal radiotherapy and tandem high-dose chemotherapy in patients with high-risk medulloblastoma.

Authors:  Ji Won Lee; Do Hoon Lim; Ki Woong Sung; Hee Won Cho; Hee Young Ju; Ju Kyung Hyun; Keon Hee Yoo; Hong Hoe Koo; Yeon-Lim Suh; Yoo-Sook Joung; Hyung Jin Shin
Journal:  Cancer Med       Date:  2020-06-30       Impact factor: 4.452

8.  What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?

Authors:  Jihane Adelon; Christelle Dufour; Stéphanie Foulon; Julien Masliah Planchon; David Meyronnet; Franck Bourdeaut; Gilles Palenzuela; Fanny Fouyssac; Sandra Raimbault; Emilie De Carli; Sébastien Klein; Anne Pagnier; Anne-Isabelle Bertozzi; Angélique Rome; Audrey David; Sylvie Chabaud; Cécile Faure-Conter
Journal:  J Neurooncol       Date:  2021-06-02       Impact factor: 4.130

9.  Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children.

Authors:  Léa Guerrini-Rousseau; Rachid Abbas; Sophie Huybrechts; Virginie Kieffer-Renaux; Stéphanie Puget; Felipe Andreiuolo; Kévin Beccaria; Thomas Blauwblomme; Stéphanie Bolle; Frédéric Dhermain; Audrey Longaud Valès; Thomas Roujeau; Christian Sainte-Rose; Arnault Tauziede-Espariat; Pascale Varlet; Michel Zerah; Dominique Valteau-Couanet; Christelle Dufour; Jacques Grill
Journal:  Neuro Oncol       Date:  2020-11-26       Impact factor: 12.300

Review 10.  Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial.

Authors:  Simon Bailey; Nicolas André; Lorenza Gandola; Maura Massimino; Stefan Rutkowski; Steven C Clifford
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.